# Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients

> **NCT05972928** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Beni-Suef University** · enrollment: 80 (estimated)

## Conditions studied

- Polycystic Ovary Syndrome

## Interventions

- **DRUG:** Sitagliptin 100mg

## Key facts

- **NCT ID:** NCT05972928
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-30
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972928, "Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05972928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*